En als je de laatste VIER berichten van dit Amerikaanse platform leest, dan zie je dat de betreffende onderzoeken allemaal achterlopen op die van VIVO!
February 3, 2022 News by Patricia Inacio PhD
Dosing Begins in Trial of CY6463 for Patients With Cardiovascular Risk
Patient dosing has begun in Cyclerion Therapeutic’s Phase 2a trial testing CY6463, a disease-modifying therapy for people with Alzheimer’s disease who have cardiovascular risk factors — health conditions that increase the risk of heart disease. The experimental oral therapy is designed to improve cognition and function in people with…
February 1, 2022 News by Steve Bryson PhD
Aduhelm Phase 4 ENVISION Study to Increase Participant Diversity
Up to 18% of U.S. participants in ENVISION — a Phase 4 post-marketing study of Aduhelm (aducanumab) in early Alzheimer’s disease — will now be enrolled from African American and Latinx populations, the therapy’s developers said in a press release. The aim is to increase diversity in the trial,…
January 31, 2022 News by Margarida Maia PhD
First Patient Joins Tau NexGen Study in Early-onset Alzheimer’s
A first patient has joined the Tau NexGen study that will test two antibodies in combination — targeting both amyloid and tau proteins — as a potential treatment for early-onset Alzheimer’s disease caused by genetic mutations, according to a press release. Tau NexGen is a newly added arm…
January 27, 2022 News by Yedida Y Bogachkov PhD
First Patient Dosed in Resumed Trial of Montelukast for Alzheimer’s
The first patient has been dosed in the resumed Phase 2a clinical trial of montelukast for mild to moderate Alzheimer’s disease. IntelGenx, the company running the study known as BUENA (NCT03402503), suspended the trial in late 2020 due to increased concern regarding the COVID-19 pandemic. “Resumption of…